ECEESPE2025 Poster Presentations Endocrine Related Cancer (76 abstracts)
Endocrine toxicity constitutes an independent predictor of survival in patients with extensive stage small cell lung cancer
Emmanouil Panagiotou 1 , Ioannis Vathiotis 1 , Maria Effrosyni Livanou 1 , Athanasios Trimis 1 , Aspasia Manta 2 , Athina Asimakopoulou 1 , Andriani Charpidou 1 , Konstantinos Syrigos 1 & Melpomeni Peppa & 2
1Third Department of Medicine, Sotiria General Hospital for Chest Diseases, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; 2Endocrine Unit, Second Propaedeutic Department of Internal Medicine, Research Institute and Diabetes Center, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
JOINT3848
Endocrine immune-related adverse events (e-irAEs) complicate the treatment of patients with lung cancer (LC) treated with immunotherapy. Although the incidence of e-irAEs as well as their impact on survival outcomes in LC cancer patients has been previously reported, evidence is limited for patients with extensive-stage small-cell lung cancer (ES SCLC). We retrospectively assessed patients with SCLC receiving chemoimmunotherapy in the first-line treatment setting at “Sotiria” General Hospital for Chest Diseases, Greece. Kaplan-Meier curves were used to calculate real-world survival outcomes and cox proportional hazards regression analysis was utilized to identify associations with e-irAEs. In total, 193 patients were included, 73 patients receiving atezolizumab plus platinum-etoposide (EP) and 120 patients receiving durvalumab plus EP. 31 patients (17. 1%) experienced an e-irAE. The reported e-irAEs included hypothyroidism in 21 patients (11. 6%), hyperthyroidism in 7 patients (3. 9%) and hypophysitis in 3 patients (1. 7%). e-irAEs were mild (grade 1-2) in almost all (96. 8%) patients. Discontinuation of immunotherapy was not required, although treatment was temporarily interrupted in 2 patients with hypophysitis. The incidence rate and type of e-irAEs were similar among patients receiving atezolizumab and durvalumab (18. 2% vs 16. 5%, P = 0. 936). Median overall survival was higher in patients with e-irAEs compared to patients without (17. 9 vs 9. 6 months, HR: 0. 42, 95% CI 0. 26 – 0. 70, p <0. 001). The difference in real-world overall survival remained statistically significant in multivariate analysis. Median progression-free survival was also higher (7. 5 vs 6. 3 months, HR: 0. 60, 95% CI: 0. 39 – 0. 93, P = 0. 02). In conclusion, the development of e-irAEs remained an independent predictor of survival outcomes in patients ES-SCLC receiving chemoimmunotherapy after extended recruitment and follow-up.
Volume 110
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2025 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more